Cite

    Schäferhoff, M. et al. (2022). Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries. Lancet. 10 (7), pp. e1045-e1052. [Online].